Touchlight, a global CDMO specialising in enzymatic DNA production, is delighted to announce that it has been awarded a tender to deliver enzymatic DNA as part of CPI’s tender process for the establishment of its RNA Centre of Excellence.
CPI, a technology innovation centre in the UK, has selected Touchlight to supply research and GMP-grade enzymatic DNA for the development and manufacturing of RNA therapeutics and vaccines.
With Touchlight’s dbDNA platform already used in two clinical studies as a critical starting material for mRNA production, Touchlight will contribute its expertise and cutting-edge technology to facilitate the development and scale-up of novel RNA therapeutics.
Touchlight’s dbDNA offers unparalleled advantages in terms of scalability, quality, and safety, making it an ideal choice to enable CPI’s RNA Centre of Excellence.
Karen Fallen, CEO of Touchlight said “We’re excited to support CPI and its partners in the development and manufacture of mRNA products. CPI’s RNA Centre of Excellence promises to be a crucial part of the mRNA supply chain in the UK, helping to advance mRNA vaccines and therapies more quickly.”
